Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL). This is an ASCO Meeting Abstract from the 2024 ASCO ...

The approval of MVR-EX103 by INCI is a significant milestone for the Company in advancing international partnerships and market expansion. ImmVira has entered a commercial partnership with a ...

SUZHOU, China, April 10, 2025 /PRNewswire/ -- EonveLab, a subsidiary of ImmVira Group ("ImmVira," or the "Company"), recently announced that its in-house developed engineered exosome product, ...